An interventional study of Dietary Supplement with Proprietary Herbal Extract Blend and GABA and Placebo in Healthy and Menopause, sponsored by Olly, PBC. Completed at 1 site in United States. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Olly, PBC · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are:
Olly, PBC is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Oral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period.
Other: Placebo
Oral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period.
Dietary Supplement: Dietary Supplement with Proprietary Herbal Extract Blend and GABA
Eligible subjects will receive active product to take daily for seven days
Eligible subjects will receive Placebo to take daily for seven days
Daily Diary - 24hr
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Daily Diary.
Time frame: from enrollment to the end of study at seven days
Mobile App - 24hr
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Mobile Application.
Time frame: from enrollment to the end of study at seven days
Daily Dairy - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Time frame: from enrollment to the end of study at seven days
Mobile App - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Time frame: from enrollment to the end of study at seven days
Green Climacteric Scale (GCS) - Days 1-6
To assess changes in stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Time frame: from enrollment to the end of study at seven days
Menopause-Specific Quality of Life (MENQOL) - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Time frame: from enrollment to the end of study at seven days
Pittsburgh Sleep Quality Index (PSQI) - Day 7
To assess changes on mood, stress and sleep scores at 7 days post treatment
Time frame: from enrollment to the end of study at seven days
Perceived Stress Scale (PSS) - Day 7
To assess changes on mood, stress and sleep scores at 7 days post treatment
Time frame: from enrollment to the end of study at seven days
Profile of Mood States questionnaire (POMS) - Day 7
To assess changes on mood, stress and sleep scores at 7 days post treatment
Time frame: from enrollment to the end of study at seven days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Olly, PBC